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Traumatic brain injury (TBI) has become the signature wound of wars in Afghanistan and
Iraq. Injury may result from a mechanical force, a rapid acceleration-deceleration move-
ment, or a blast wave. A cascade of secondary cell death events ensues after the initial
injury. In particular, multiple inflammatory responses accompany TBI. A series of inflam-
matory cytokines and chemokines spreads to normal brain areas juxtaposed to the core
impacted tissue. Among the repertoire of immune cells involved, microglia is a key player
in propagating inflammation to tissues neighboring the core site of injury. Neuroprotec-
tive drug trials in TBI have failed, likely due to their sole focus on abrogating neuronal cell
death and ignoring the microglia response despite these inflammatory cells’ detrimen-
tal effects on the brain. Another relevant point to consider is the veracity of results of
animal experiments due to deficiencies in experimental design, such as incomplete or
inadequate method description, data misinterpretation, and reporting may introduce bias
and give false-positive results. Thus, scientific publications should follow strict guidelines
that include randomization, blinding, sample-size estimation, and accurate handling of all
data (Landis et al., 2012). A prolonged state of inflammation after brain injury may linger for
years and predispose patients to develop other neurological disorders, such as Alzheimer’s
disease.TBI patients display progressive and long-lasting impairments in their physical, cog-
nitive, behavioral, and social performance. Here, we discuss inflammatory mechanisms
that accompany TBI in an effort to increase our understanding of the dynamic pathological
condition as the disease evolves over time and begin to translate these findings for defining
new and existing inflammation-based biomarkers and treatments for TBI.
Keywords: head trauma, microglia, inflammatory response, secondary cell death, anti-inflammatory therapy, brain
imaging
INTRODUCTION
Traumatic brain injury (TBI) is characterized by a damage to the
brain as a result of a violent impact, blow or jolt to the head
that causes the brain to strike the inside of the skull or when
an object perforates the skull and reaches brain tissue. The most
recent estimates of the incidence and prevalence of TBI indicate
that each year 235,000 Americans are hospitalized for non-fatal
TBI, 1.1 million are treated in emergency, and 50,000 die (Corri-
gan et al., 2010). Common features of TBI include bruising, torn
tissues, bleeding, and physical damage to the brain resulting in
long term complications or death. It can be classified based on its
severity, anatomical areas affected, and causative forces. Depend-
ing on the extent of damage to the brain, TBI varies from mild to
moderate to severe. Serious secondary events may also occur, such
as oxidative stress, massive edema, and alterations of endogenous
neurotransmitter mechanisms, as depicted in Figure 1. In the case
of mild TBI, the patient may remain conscious or faint for a few
seconds or minutes. Characteristic symptoms of mild TBI include
headache, confusion, lightheadedness, dizziness, blurred vision or
tired eyes, ringing in the ears, bad taste in the mouth, fatigue or
lethargy, a change in sleep patterns, behavioral or mood changes,
and trouble with memory, concentration, attention, or thinking
(National Institute of Neurological Disorders and Stroke, National
Institutes of Health). In moderate to severe TBI similar symptoms
may occur, but with worse manifestations. For example headaches
may become intermittent, repeated vomiting or nausea, seizures,
inability to awaken from sleep, dilation of one or both pupils of the
eyes, slurred speech, weakness or numbness in the extremities, loss
of coordination, and increased confusion, restlessness, or agita-
tion. War-related TBI is usually associated with injury to the brain
due to an improvised explosive device (IED) blast during military
conflicts (Bogdanova and Verfaellie, 2012; Duckworth et al., 2012;
Goeller et al., 2012). When a frontal blast wave encounters the
head, a shock wave is transmitted through the skull, cerebrospinal
fluid (CSF), and tissue, causing negative pressure at the contrecoup
that may result in cavitation (Goeller et al., 2012).
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FIGURE 1 | Proposed secondary cell death mechanism afterTBI. A
sensitive balance in neurotrophic factor secretion and cytokine expression
dictates the fate of injured neurons towards pro-survival (early stage) and
pro-death (chronic stage) cellular processes after TBI. Upregulation of
neurotrophic factors and cytokines may renderneuroprotectionin the early
stage, whereas downregulation of neurotrophic factors coupled with
continued upregulation of specific pro-death cytokines, as well as the onset of
oxidative stress, massive edema, and alterations in endogenous
neurotransmitter function may promote neurodegeneration in the chronic
stage.
Patients with varying severity of TBI often struggle with phys-
ical and cognitive impairments for months, or years; and some
never reach full recovery. An estimated 43.3% of Americans
have residual disability 1 year after injury (Corrigan et al., 2010).
Although TBI is typically believed to be a static pathological insult
from a single event, previously unrecognized clinical symptoms
can arise many years after the initial injury (Giunta et al., 2012).
The most recent estimate of the prevalence of US civilian residents
living with disability following hospitalization with TBI is 3.2–5.3
million (Corrigan et al., 2010; Coronado et al., 2011). Thus, greater
efforts should center on this sector of the population living and
aging with post-TBI sequelae.
In this mini-review, we bring attention to microglia, which pos-
sess a double-edge sword function, in that microglia can mount
both pro-survival and pro-death actions after TBI occurrence.
We propose new and present inflammation-based biomarkers
that may enhance regenerative abilities and decrease degener-
ative events associated with microglial response for the treat-
ment of TBI. Microglia exert neuroprotection by sequestering, via
phagocytosis, foreign bodies that aberrantly penetrate the brain
(Noda et al., 2011; Voss et al., 2012). Unfortunately during aging,
microglial cells also display reduced phagocytic capacity (Fiala
et al., 2005; Kohman, 2012). The challenge for developing therapies
targeting microglial function is to manipulate microglia activation
toward a reparative process that could retard, or even halt the
progressive pathological symptoms of TBI and its co-morbidity
factors.
IMMUNE RESPONSE AND MICROGLIA
Activation of the immune system in the central nervous system
(CNS) has become increasingly recognized as a key component
of the normal process of aging, but also of the pathological onset
and progression of many neurological disorders including TBI
and neurodegenerative diseases. There are three phenotypic states
of microglia-based on developmental and pathophysiologic stud-
ies: (i) resting, ramified; (ii) activated non-phagocytic [or antigen
presenting cell (APC)-like] found in areas involved in CNS inflam-
mation; and (iii) reactive, in which phagocytic microglia is present
in areas of trauma or infection (Frei et al., 1987; Suzumura et al.,
1987; Williams et al., 1992; Panek and Benveniste, 1995; Walker
et al.,1995). With respect to activation,macrophages and microglia
are able to polarize into two major subtypes, categorized as M1
or M2 (Mosser, 2003; Gordon and Taylor, 2005). This “classi-
cal” or M1 subtype excessively secretes proinflammatory cytokines
and promotes cell-mediated immunity (Mosser, 2003; Gordon
and Taylor, 2005). It is marked by production of high levels of
interferon-gamma (IFN-γ), tumor necrosis factor (TNF)-α, inter-
leukin (IL)-1, IL-12, and low levels of IL-10. The M1 phenotype
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may be activated when microglia contact HIV proteins (such as
transactivator of transcription [Tat] bind toll-like receptors 3 or 4
as well) (Suh et al., 2009).“Alternatively activated”or M2 microglia
tend to dampen (Bruce-Keller et al., 2001) inflammation, clear cel-
lular debris (including amyloid plaques),and produce very low lev-
els of TNF-α, IL-1, IL-12, and high amounts of anti-inflammatory
IL-10 and transforming growth factor (TGF)-β, and suppressor
of cytokine signaling (SOCS) (Mosser, 2003; Gordon and Taylor,
2005; Qin et al., 2006; Akhtar et al., 2010). These two phenotypes,
respectively, belong to the type ii or iii microglial states. Further,
the factors which cause polarization to M1 or M2 reinforce the
maintenance of that phenotype in a cycle-like manner.
The initial inflammatory response after TBI results in neu-
ronal injury and disruption of the blood-brain barrier (Smith
et al., 1997; Nagamoto-Combs et al., 2007; Namas et al., 2009).
Microglial cells become activated within minutes, and resemble
peripheral macrophages by acting as APCs releasing proinflam-
matory cytokines and chemokines (Town et al., 2005; Cao et al.,
2012). Activated microglia also produce other neurotoxic prod-
ucts after injury such as nitric oxide (NO) and superoxide free
radicals that generate reactive oxygen species (ROS) and reactive
nitrogen species (RNS). In animal models of cortical controlled
impact (CCI); fluid percussion brain injury in rats; combined
unilateral lesion of the primary motor cortex and of the lateral
pre-motor cortex in rhesus monkeys, microglial cells remain in
their activated state for at least 1 year, especially in the thalamic
area (Smith et al., 1997; Nagamoto-Combs et al., 2007; Nagamoto-
Combs and Combs, 2010; Jacobowitz et al., 2012; Jin et al., 2012).
Human postmortem studies have shown microglial activation
17 years after TBI in subcortical brain areas (Ramlackhansingh
et al., 2011). These accrued results suggest the persistence of a
chronic inflammatory stage mediated by microglia.
A novel feature of activated microglial cells is the delicate
cytokine profile they acquire upon brain insult. Microglial cells
may share common markers for activated macrophages including
CD68, CD45, and major histocompatibility complex II (MHC-
II) (Town et al., 2005; Cao et al., 2012). The sensitive balance
in cytokine expression may dictate the fate of injured neurons
toward pro-survival or pro-death mechanisms, as illustrated in
Figure 2.
Microglial cells exist in at least two functionally distinguishable
states once activated – namely a phagocytic phenotype (innate
activation) or the aforementioned antigen presenting phenotype
(adaptive activation) that is seen post-TBI (Town et al., 2005;
Giunta et al., 2012). When injury to the CNS occurs, activated
microglial cells acquire a predominant proinflammatory profile.
FIGURE 2 | Evolution of penumbra afterTBI. The brain tissue
surrounding the impacted core of TBI can become vulnerable to cell death
due to spreading waves of pro-death cytokine mediators. This at-risk brain
tissue corresponds to the penumbra which comprises the transition zone
between injury and repair (top graphics). A therapeutic window exists for
the repair process to abrogate the injury progression. When the brain cell
faces damage, it suffers from two kinds of injuries, namely primary
(necrosis) and secondary (apoptosis) cell death (middle graph).
Neurovascular repair, such as transplantation of stem cells, upregulation of
neurotrophic factors, and inhibition of pro-death cytokines,can rescue
against the secondary cell death. The penumbra is traditionally defined as
an area with mild to moderate reductions in cerebral blood flow (CBF,
bottom graph). Such evolution of penumbra after brain injury was originally
observed in stroke (Lo, 2008).
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If microglia cells are challenged with certain pathogen-associated
molecular patterns (particularly CpG-DNA), they activate a mixed
response characterized by enhanced phagocytosis and proinflam-
matory cytokine production, as well as adaptive activation of T
cells (Giunta et al., 2012). Among the repertoire of proinflamma-
tory cytokines, IL-1-β and TNF-αplay a pivotal role before, during,
and after microglia activation. Once secreted, these cytokines can
bind specific receptors to increase the amount of inducible nitric
oxide synthase (iNOS). Also, they can act as molecular inducers
of programmed cell death or apoptosis as shown in animal and
human studies of neurodegenerative diseases like Alzheimer’s dis-
ease (AD) (Heneka et al., 1999; Venters et al., 2000; Combs et al.,
2001). In addition, after severe TBI, it has been shown that there
is a pronounced increase of IL-6, IL-8, TNF-α, and IL-1-β mRNA
in human post mortem tissue (Frugier et al., 2010).
Microglia not only express a gamut of proinflammatory
cytokines (IL-1, IL-6, TNF-α), but also secrete a myriad of anti-
inflammatory cytokines (IL-1 receptor antagonist, IL-4, IL-10) and
neurotrophic factors brain-derived neurotrophic factor (BDNF,
NGF, TGF-β). Of note, these neurotrophic factors are not exclu-
sively secreted by activated microglia cells or macrophages; indeed
these neurotrophic factors are synthesized and secreted by a myr-
iad of cells (i.e., stroma cells, T cells, and astrocytes) within the
CNS during inflammatory conditions (Murphy et al., 1977; Pál
et al., 2012). Cytokines are small proteins expressed/secreted by
microglia under inflammatory conditions. Important exogenous
factors capable of cytokine induction in microglia are viral enve-
lope proteins, bacterial cell wall components such as, lipopolysac-
charides (LPS) and leukotriene A (LTA); also bacterial DNA, and
prions (Heppner et al., 2001). Likewise, endogenous inducers act as
inflammatory mediators, such as platelet-activating factor (PAF),
lipids, serum proteins, or complement factors; additionally, dis-
turbances in ATP and [K+] levels may cause microglia activation
(Hanisch, 2002). Thus, shifting the cytokine profile of microglia
toward a pro-survival phase (anti-inflammatory cytokines) may
increase neuroprotection and regeneration of the CNS after TBI.
In the subsequent sections, we discuss both pro-survival and pro-
death functions of microglia and identify avenues for therapeutic
development,as well as to propose potential biomarker approaches
that will maximize the dynamic features of microglia. In the end, a
multi-pronged strategy focusing on microglial function may reveal
novel therapies and biomarkers for a better understanding of TBI
treatment and pathology.
HARNESSING MICROGLIAL PRO-SURVIVAL FUNCTIONS
Strategies designed to target specific molecules may be able to
manipulate the cytokine profile of the activated microglia. There
are several molecules that may be suitable to promote neu-
ronal survival after damage. Among the candidates, granulocyte-
macrophage colony stimulating factor (GM-CSF), and colony
stimulating factor 1 (CSF-1) have demonstrated to be potent stim-
uli for microglia in vitro (Sawada et al., 1990; Suzumura et al., 1990;
Streit et al., 2000). With the proper signaling cues, microglia may
shift toward producing more of the neuroprotective substances
(e.g., IL-10, IL-1ra, and TGF-β) soon after injury. The direct benefit
of these molecules is immediate suppression of proinflammatory
cytokines. TGF-β also has been shown to exert neuroprotective
effects after injury, including improved function, decreased lesion
size, and reduced iNOS production (Hamada et al., 1996; Tyor
et al., 2002).
We propose that potential activated microglia-related biomark-
ers should possess the following features: (a) have high specificity
and sensitivity for activated microglia, (b) stimulate microglia to
polarize into the M2 phenotype, (c) promote synaptic, neuronal
plasticity, and cell survival at a close or distal range from the area
of injury, and (d) reduce the inflammatory response post-TBI
(Mosser, 2003; Gordon and Taylor, 2005; Ben Achour and Pas-
cual, 2010). Potential microglia-related biomarker to which above
criteria could be applied to stimulate microglia into the M2 pheno-
type may be the chemokine fractalkine, CX3CL1, and its receptor
CX3CR1. Both are constitutively expressed in the nervous system.
The ligand is expressed exclusively by neurons and endothelial
cells, whereas the receptor is s expressed by microglia, astrocytes,
and neurons (Rancan et al., 2004). In vitro and in vivo models
of neurological conditions and brain inflammation also reported
how CX3CL1 reduces microglia toxicity and, consequently, neu-
ronal damage (Zujovic et al., 2000; Mizuno et al., 2003; Cardona
et al., 2006; Bhaskar et al., 2010; Noda et al., 2011; Pabon et al.,
2011). Interestingly enough, CX3CL1 and CX3CR1 reduce brain
damage in a rodent ischemic model via an adenosine-dependent
mechanism (Cipriani et al., 2011). Microglial activation should
not be linked only to deleterious effects. There are instances where
activated microglia may have a protective role in TBI (Urrea et al.,
2007). Case in point, at 3 h after moderate fluid percussion in rats, a
new population of cells was recognized in the sub-ventricular zone
of the traumatized hemisphere (Urrea et al., 2007). Double labeling
confocal microscopy showed newly formed astrocytes, oligoden-
drocytes, and neurons co-localized with macrophages/microglia
even after days on injury. These findings suggest that TBI stim-
ulates a widespread cellular proliferation after injury, and that
microglial activation may be involved in the observed focal neu-
rogenesis in the dentate gyrus of the hippocampus (Urrea et al.,
2007).
Most TBI animal studies indicate that extended microglial acti-
vation at the focal site of injury becomes detrimental over time
(Hanisch and Kettenmann, 2007; Ramlackhansingh et al., 2011;
Cao et al., 2012; Mannix and Whalen, 2012). Nevertheless, equally
compelling studies suggest that persistent microglial activation
in regions remote from focal injury might promote brain repair
(Nagamoto-Combs et al., 2007, 2010; Thiel et al., 2010), possibly
via neurotrophic factor secretion, especially BDNF, proximal and
distal to the injured tissue (Krueger et al., 2011; Rostami et al.,
2011; Cekic et al., 2012; Colak et al., 2012; Ma et al., 2012; Shi
et al., 2012). For instance, in non-human primates even 6 months
after injury microglial cells continue to release BDNF and its
receptor subtypes TrkB[gp145] and TrkB[TK-] around the cortical
lesion site and in the spinal cord (Nagamoto-Combs et al., 2007).
Double labeling studies showed that a subpopulation of CD68-
immunoreactive microglia/macrophage co-expressed BDNF in
the cortex and spinal cord, and also TrkB[gp145] or TrkB[TK-]
in the spinal cord; whereas cytokine expression of TNF-α, IL-6,
and IL-1-β was less prominent at the 1, 6, and 12-month intervals,
suggesting that immediate inflammatory responses had subsided
(Nagamoto-Combs et al., 2007). Yet, in a CCI rat model there is a
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decline in BDNF-mRNA and protein levels measured at 1–14 days
post injury (Schober et al., 2012). Moreover, specific BDNF poly-
morphisms may not be involved in TBI pathology (Bagnato et al.,
2012). Notwithstanding these inconsistencies, the findings are
encouraging because they suggest that the prolonged microglial
activation plays an important role in neurotrophic/tropic signal-
ing, and identifying the appropriate growth factors (i.e., BDNF
polymorphism) should facilitate in recovery process of the TBI
brain. Thus, more studies are warranted to decipher the molecular
cues released by activated microglia proximal and distal to the site
of injury, and nurture such therapeutic molecules to be robustly
and stably expressed not only at these brain regions vulnerable to
secondary cell death, but also to the major impacted brain areas in
order to sequester the extent of injured brain after TBI.
INCREASING PHAGOCYTIC ACTIVITY OF MICROGLIA
An equally appealing function of microglia is their phagocytic
activity which may rescue neurons from degeneration. Enhancing
the phagocytic state of microglia at early stage post-TBI may retard
cell death signals to spread to damaged neurons and neighboring
cells (Jeon et al., 2012; Schafer et al., 2012; Tamashiro et al., 2012).
Furthermore, there are many studies that have documented the
process of cell autophagy as neuroprotective after TBI (Clark et al.,
2008; Lai et al., 2008; Liu et al., 2008; Venkatesan et al., 2010).
Indeed, nearby neurons and astrocytes close to the site of injury
are capable of clearing out cell debris after brain injury (Zhang
et al., 2008; Loov et al., 2012). An increase in autophagosomal for-
mation proteins, such as microtubule-associated protein 1 light
chain 3 (LC3) and beclin 1, has been detected in neurons and
astrocytes at 1-h, 3-h, 32 days post-TBI (Zhang et al., 2008). How-
ever, autophagy may exacerbate the pathological manifestations
of TBI (Bigford et al., 2009; Luo et al., 2011), likely due to aber-
rant clearance of healthy cells in addition to degenerating cells.
Accordingly, for the phagocytic activity of microglia to attenuate
the progression of TBI pathology, a regulatory mechanism should
be devised to enhance the therapeutic autophagy, while blocking
its deleterious side effects.
A potent approach to manipulating microglial phagocytic func-
tion is by stimulating neural progenitor cells (NPCs). Mouse
NPCs possess a secretory protein profile distinct from other brain
cells; specifically proteins that modulate microglial activation and
phagocytosis (Mosher et al., 2012). That a close modulatory inter-
action exists between these two cell types at the protein level
suggests that microglia and NPCs may influence each other func-
tions and activity. Some of the factors secreted in large amounts by
NPCs include tissue inhibitor of metalloproteinase type-1 (TIMP-
1), vascular endothelial growth factor (VEGF), and haptoglobin,
which are well known immunomodulatory proteins or regulators
of microglia (Forstreuter et al., 2002; Hanisch and Kettenmann,
2007). Based on this knowledge, an envisioned drug for TBI
may be potent immunomodulatory proteins that could foster the
therapeutic phagocytic activity of microglia.
REDIRECTING PRO-DEATH MICROGLIAL FUNCTIONS
Inactivating the pro-death inflammatory response of microglial
cells is equally effective in combating the secondary cell death
associated with TBI (Kapadia et al., 2008; Chen et al., 2011; Tsai
et al., 2011). Recent pharmacologic strategies against TBI-induced
secondary cell death employ inhibitors of oxidative stress and
microglial activation. A high dose (100 mg/kg) pre-treatment
with apocynin, an NADPH oxidase assembly inhibitor that
retains proinflammatory profile of microglia, produces therapeu-
tic potential against murine models of TBI (Choi et al., 2012;
Zhang et al., 2012). One week after TBI, microglial activation
remained, but ROS production was inhibited by apocynin in the
hippocampal CA3 pyramidal neurons; they also found reduced
BBB disruption, and neuronal rescue from cell death associated
with TBI (Choi et al., 2012).
New therapies to attenuate exacerbation of microglia activa-
tion have emerged thanks to the study of potential biomarkers
identified in models of acute spinal cord injury (SCI). Inter-
estingly, an overlap in the cytokine profiles expressed by SCI
rodents and human subjects has been recently demonstrated, in
that rodent and human released in an SCI injury-dependent man-
ner IL-6, IL-8, and monocyte chemoattractant protein 1 (MCP-1)
(Stammers et al., 2012). A promising neuroprotective approach
is the use of the antibiotic minocycline. In SCI animal models,
minocycline has shown therapeutic effects in reducing microglial
activation, excitotoxicity, and neuronal and oligodendrocyte cell
death associated with mitochondrial stabilization (Teng et al.,
2004; Festoff et al., 2006; Yune et al., 2007; Lee et al., 2012).
Of note, a recent study demonstrated increased motor recov-
ery in human patients suffering from acute SCI after 7 days of
minocycline treatment relative to patients treated with the placebo
drug (Casha et al., 2012) In the field of stem cell therapy, stud-
ies have also shown that a chemokine/cytokine (i.e., inflamma-
tory) response may actually guide the migration of stem cells
from the periphery to the site of brain injury, thereby allow-
ing efficient brain bioavailability of the grafted cells’ secreted
therapeutic molecules (Borlongan, 2011; Borlongan et al., 2011).
Such inflammation-mediated cell migration suggest that a mod-
est cytokine/chemokine upregulation aids stem cells in reaching
their brain injured target areas. Recognizing the balance between
proinflammatory and anti-inflammatory microglial function may
provide new targets for arresting TBI-induced secondary cell
death.
CONTEMPLATINGMICROGLIA-BASED BIOMARKERS FOR TBI
In parallel to developing treatments for TBI, utmost considera-
tion for research investigations should be devoted to exploring
biomarkers for TBI which will help optimize therapeutic inter-
vention, in that the proper timing for treatment initiation will be
guided by onset or peak time window of secondary cell death as
may be captured by novel biomarker tools.
CYTOKINE PROFILING
Cytokine profiling of microglial cells may lead to identification of
specific proteins that regulate microglia (e.g., BDNF) and measur-
ing these proteins in the blood or CSF may provide clues on the
status of the TBI patient. Unraveling the cytokine and chemokines
profile of activated microglia could lead to the identification of
specific proteins that regulate microglia response after TBI (e.g.,
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BDNF, NGF, and TGF-β). This approach would have to tackle
the paracrine and autocrine roles, as well as interactions between
cytokines, chemokines, and neurotrophic/tropic factors. Defin-
ing a cytokine profile for activated microglia in TBI can give us
new insights on known neuroprotective approaches post-TBI. This
knowledge may translate into the human clinical scenario by mea-
suring these recognized proteins in the blood, plasma, or CSF
and provide clues on the status of the TBI patient. For instance,
cerebral microdialysis is a well-established laboratory tool that is
increasingly used as a bedside monitor to provide on-line analysis
of brain tissue biochemistry during neurointensive care (Tisdall
and Smith, 2006). In a microdialysis study 12 patients suffering
from diffuse severe TBI, defined as a post-resuscitation Glasgow
Coma Score ≤8, were monitored over a period of 5 days. Their
cerebral fluid, arterial and jugular venous plasma samples were
screened for a cytokine and chemokine dataset using a principal
component analysis and partial least squares discriminant analysis
to demonstrate the pattern of production following TBI, distinct
phases of the humoral inflammatory response and the differing
patterns of response in brain and in peripheral blood (Helmy
et al., 2012). Brain tissue microdialysis can become an established
technique for monitoring acute and chronic TBI if future studies
are capable of identifying an overlap in microglial cytokine pro-
file against the microdialysis data analysis. Potential biomarkers
identified in rat models of TBI that should be included in the
repertoire of microglial profiling and overall brain tissue profil-
ing by microdialysis may include epithelial/endothelial tyrosine
kinase (Wu et al., 2012), poly(ADP-ribose) polymerase-1 (d’Avila
et al., 2012), and myeloid differentiation primary response protein
88 (Li et al., 2011). In addition to this emerging cytokine pro-
file, novel cytokines and associated proteins may be detected via
high throughput screening assays (e.g., microRNA analysis) using
blood, CSF, or tissue samples from TBI patients and animal mod-
els from time of impact and over different periods of secondary
cell death evolution.
DETECTING PHAGOCYTIC PROFILE
Detecting phagocytic profile of microglia may reveal close mol-
ecular and cellular association between NPCs and stem cells. In
addition, measuring levels of NPCs or stem cells via imaging
modalities (functional MRI) may reveal the phagocytic activity
of microglia. The identification of potent immunomodulatory
proteins in the phagocytic profile of microglia, NPCs, and stem
cells in general could help us elucidate the overlap in modulatory
and phagocytic functions among these cell types. It seems tangi-
ble to measure levels of NPCs or stem cells via imaging modalities
(e.g., functional MRI) to provide real-time status of the phagocytic
activity of microglia (Yu et al., 2010). Likewise, we could attempt
to correlate already known phagocytic biomarkers (e.g., LC3) with
those of inflammation and apoptosis to establish a causal rela-
tionship among these three critical cellular processes in the TBI
brain. For example, in a lateral moderate fluid percussion injury
model of TBI in adult rats, microarray analyses revealed apparent
time-dependent expression changes in 23 apoptosis-related genes,
including inflammatory cytokines such as IL-1-α, IL-1-β, and TNF
which immediately increased at 3 h following the injury (Shojo
et al., 2010). Thus, these time-dependent gene expression profiles
elucidate the progression of the secondary cell death process of
apoptosis, shown in this study as an ensuing event associated with
inflammation (Shojo et al., 2010).
ASSESSING THE LEVEL OF “PROINFLAMMATORY RESPONSE OF
MICROGLIA”
Assessing the level of “proinflammatory response of microglia”
could be measured via blood/CSF assays (Ziebell et al., 2011;
Jin et al., 2012). The intent here is to visualize a threshold of
pro-inflammation that is therapeutic (i.e., serving as signaling cue
for stem cell migration from periphery to the injured brain), and
has not reached a level that could invoke the deleterious neuroin-
flammatory response responsible for exacerbation of TBI patho-
logical symptoms. For example, measuring S-nitrosoglutathione
(GSNO), a nitrosylation-based signaling molecule, could reveal
brain levels of peroxynitrite and oxidative metabolites, which
when reduced levels are detected may indicate protection of the
neurovascular unit integrity (Khan et al., 2009, 2011). Coinciden-
tally, the detection of increased neurotrophic factors produced by
constant low levels of GSNO treatment over time may represent
enhanced synaptic plasticity (Khan et al., 2009, 2011). Accordingly,
assessment of surrogate markers of GSNO involving peroxynitrite
and oxidative metabolites, and neurotrophic factors may pro-
vide insights on neurovascular integrity and synaptic plasticity
in TBI.
CONCLUSION
The major pro-survival feature of microglia is their phagocytic
activity. Identifying the signaling factors that nurture microglia
to preserve their regenerative function after injury versus the
predominating inflammatory activity (e.g., neuroinflammation)
will provide insights into homeostatic mechanisms in maintain-
ing a healthy brain. An appealing characteristic of microglia,
which deserves more attention, is their migration to the site of
injury. However, the migratory mechanisms thriving microglia
to populate the CNS after arrival at the injured brain remain
poorly understood. An in-depth examination of the molecu-
lar cues that regulate the anti-inflammatory response will guide
the development of effective treatments to reduce detrimental
effects of microglial activation and shift their function toward
microglia-based therapies for TBI.
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